Panitumumab

CAS No. 339177-26-3

Panitumumab( —— )

Catalog No. M22158 CAS No. 339177-26-3

Panitumumab is a fully human IgG2 monoclonal antibody targeting the epidermal growth factor receptor EGFR).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 484 In Stock
10MG 691 In Stock
25MG 1035 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Panitumumab
  • Note
    Research use only, not for human use.
  • Brief Description
    Panitumumab is a fully human IgG2 monoclonal antibody targeting the epidermal growth factor receptor EGFR).
  • Description
    Panitumumab is a fully human IgG2 monoclonal antibody targeting the epidermal growth factor receptor EGFR).
  • In Vitro
    Western Blot Analysis Cell Line:EGFR-expressing NCI-H1975 cells, NCI-H1650 cells and CHO cells Concentration:2, 20, 200, 2000 nM Incubation Time:3 h Result:Inhibited ligand-induced autophosphorylation of EGFR.
  • In Vivo
    Animal Model:NCI-H1975 and NCI-H1650 xenografts Dosage:25, 100, or 500 μg/mouse Administration:Intraperitoneal injection (i.p.), twice a week Result:Inhibited ligand-induced EGFR phosphorylation, tumor growth, and markers of proliferation.Decreased Ki-67 and phospho- mitogen-activated protein kinase (pMAPK) staining in both xenografts.
  • Synonyms
    ——
  • Pathway
    Angiogenesis
  • Target
    EGFR
  • Recptor
    EGFR
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    339177-26-3
  • Formula Weight
    147 kDa
  • Molecular Formula
    ——
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Cohenuram M, et al.Panitumumab the first fully human monoclonal antibody: from the bench to the clinic. Anticancer Drugs. 2007 Jan;18(1):7-15.
molnova catalog
related products
  • RO 46-8443

    RO 46-8443 is the first non-peptide endothelin ETB receptor selective antagonist. RO 46-8443 displays up to 2000-fold selectivity for ETB receptors both in terms of binding inhibitory potency and functional inhibition.

  • Mutated EGFR-IN-1

    Mutated EGFR-IN-1 is a useful intermediate for the inhibitors design for mutated EGFR, such as L858R EGFR, Exonl9 deletion activating mutant, and T790M resistance mutant.

  • CK-101

    CK-101 (RX-518) is a novel potent, mutant-selective, irreversible, orally available EGFR inhibitor, overcomes T790M-mediated resistance in NSCLC.